Description: Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases. It is developing Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF developed intralesional treatment for locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory product consisting of the human L19 antibody fused to the human cytokine interleukin-2 (IL2), which is in phase II clinical trial for the treatment of non-small cell lung cancer. The company is also developing Dodekin, a human immunostimulatory product that comprises vascular targeting antibody fused to interleukin-12 that is in phase I/II clinical trial to treat advanced solid tumors; Dekavil (F8IL10), an anti-inflammatory product, which is in phase I clinical trial for the treatment of chronic inflammation; Onco IX (PHC-102), a 99mTc labelled small molecule radiotracer for the non-invasive detection of carbonic anhydrase IX (CAIX) expressing solid tumors that is in phase 1 clinical trial; and OncoFAP, a small molecule radiotracer for the non-invasive detection of various metastatic solid tumors targeting fibroblast activation protein, which is in phase 1 clinical trial. Philogen S.p.A. was founded in 1996 and is based in Sovicille, Italy.
Home Page: www.philogen.com
Via Bellaria, 35
Sovicille,
SI
53018
Italy
Phone:
39 0577 17816
Officers
| Name | Title |
|---|---|
| Mr. Duccio Neri | Co-Founder & Exec. Chairman |
| Prof. Dario Neri Ph.D. | Co-Founder, CEO , CSO, Pres of the Scientific Advisory Board & Director |
| Mr. Giovanni Neri | Co-Founder, Head of IP & Licensing and Director |
| Ms. Laura Baldi | Chief Financial Officer |
| Dr. Alfredo Covelli M.D. | Chief Medical Officer |
| Dr. Katia Lorizzo | Deputy CMO & Head of Clinical Operations |
Exchange: MI
Country: IT
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.4358 |
| Price-to-Sales TTM: | 24.355 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 140 |